Review Article
Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
Table 4
Randomized phase III trials with nab-paclitaxel in aNSCLC.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P: P value; nd: not done; sq: squamous histology of NSCLC; nsq: non squamous histology of NSCLC; AEs: adverse events; ORR: overall responce rate; RR: response rate; PFS: progression-free survival; OS: overall survival. |